Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: A comparative randomized assessment of different regimens

International Journal of Urology

Volumn 20, Issue 2, 2013, Pages 203-207

  Lai, Ming Chih ^a   Kuo, Yuh Chen ^a   Kuo, Hann Chorng ^b  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Bladder; Intravesical therapy; Painful bladder syndrome; Urothelium

Indexed keywords

HYALURONIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CAPACITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTERSTITIAL CYSTITIS; MAJOR CLINICAL STUDY; MALE; NOCTURIA; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; URINE FLOW RATE; VISUAL ANALOG SCALE;

ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; AGE FACTORS; AGED; CYSTITIS, INTERSTITIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, TEACHING; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873292637     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03135.x     Document Type: Article

References (19)

1. Butrick CW. Interstitial cystitis and chronic pelvic pain: new insights in neuropathology, diagnosis, and treatment. Clin. Obstet. Gynecol. 2003; 46: 811-23.
2. Parsons CL. Evidence-based strategies for recognizing and managing IC. Contemp. Urol. 2003; 15: 22-35.
3. Homma Y, Ueda T, Tomoe H etal. Interstitial cystitis guideline committee: clinical guideline for interstitial cystitis and hypersensitive bladder syndrome. Int. J. Urol. 2009; 16: 597-615.
4. Rajasekaran M, Stein P, Parsons CL. Toxic factors in human urine that injure urothelium. Int. J. Urol. 2006; 13: 409-14.
5. Parsons CL, Forrest J, Nickel JC etal. on behalf of the Elmiron Study Group. Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology 2002; 59: 329-33.
6. Parsons CL. Bladder surface glycosaminoglycans: efficient mechanism of environmental adaptation. Urology 1986; 27: 9-14.
7. Hurst RE. Structure, function and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J. Urol. 1994; 12: 3-10.
8. Erickson DR, Sheykhnazari M, Ordille S, Bhavanandan VP. Increased urinary hyaluronic acid and interstitial cystitis. J. Urol. 1998; 160: 1282-4.
9. Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J. Urol. 1996; 156: 45-8.
10. Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J. Urol. 1998; 159: 1862-6.
11. O'Leary MP, Sant GR, Fowler FJ Jr etal. The interstitial cystitis symptom index and problem index. Urology 1997; 49 (5A Suppl): 58-63.
12. Lubeck DP, Whitmore K, Sant GR, Alvarez-Horine S, Lai C. Psychometric validation of the O'Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology 2001; 57 (Suppl 1): 62-6.
13. Butricl CW. Intersititial cystitis and chronic pelvic pain: new insights in neuropathology, diagnosis, and treatment. Clin. Obstet. Gynecol. 2003; 46: 811-23.
14. Nickel JC, Barkin J, Forrest J etal. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 2005; 65: 654-8.
15. Sant GR, Propert KJ, Hanno PM etal. A pilot clinical trial of oral pentosan polysulphate and oral hydroxyzine in patients with interstitial cystitis. J. Urol. 2003; 170: 810-15.
16. Peeker R, Haghsheno MA, Holmang S, Fall M. Intravesical bacillus Calmetree-Guerin and dimethyl sulfoxide for treatment of classic and nuclear interstitial cystitis: a prospective, randomized double-blind study. J. Urol. 2000; 164: 1912-15.
17. Kuo HC. Comparison of intravesical botulinum toxin type A injections plus hydrodistension with hydrodistension alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009; 104: 657-61.
18. Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can. J. Urol. 2002; 9: 1454-8.
19. Glemain P, Riviere C, Lenormand L, Karam G, Bouchot O, Buzelin JM. Prolonged hydrodistention of the bladder for symptomatic treatment of interstitial cystitis: efficacy at 6 months and 1 year. Eur. Urol. 2002; 41: 79-84.